Why isn’t EFUL’s Premium Growth Translating into Stronger Earnings?
Ticker: EFU Life Assurance Limited EFUL
Analyst Briefing Date: March 30, 2026
This article summarizes EFU Life Assurance Limited’s corporate briefing, focusing on CY25 premium growth, earnings performance, portfolio positioning, and forward outlook on product expansion, regulatory changes, and industry challenges. It highlights strong top-line growth alongside pressure on profitability from investment income and rising claims.
📢 Announcement: You can now access our services and similar analyses by opening an account with us via JS Global
Don't miss:
- Top 5 Analyst Questions From Lucky Core Industries (LCI) Corporate Briefing
- 5 Reasons Why MEBL Could Continue Rising Despite a Growth Slowdown
- AKD Predicts PSO Could Double From Here
What did the management say?
Management highlighted that EFUL continues to maintain the largest private-sector life insurance balance sheet, with gross premiums reaching PKR 57.05 billion, reflecting 37% growth and the highest increase in five years. Distribution remains evenly split between conventional sales force and bancassurance channels, supporting diversified reach. The company also launched its revamped individual health plan Mukamal Sehat during the year. They stated plans to introduce corporate retirement solutions and expand into voluntary pension and annuity products following the recent SECP VPS license. Management emphasized preparation for regulatory transitions, including IFRS adoption and Risk-Based Capital requirements. Strategic focus remains on digital and inclusive insurance products, while industry risks include potential provincial sales tax on premiums and withdrawal of tax credits.
What did the numbers say?
EFU Life reported EPS of PKR 23.26 for CY25, down from PKR 29.04, despite strong premium growth. Premium revenue increased 37% to PKR 57,050 million, while net premium revenue rose 33% to PKR 52,623 million. However, investment income declined 25%, limiting total income growth to 2% at PKR 103,286 million. Profit before tax declined 20% to PKR 3,987 million, while profit after tax fell to PKR 2,442 million. Claims increased significantly, with total claims reaching PKR 12.61 billion, reflecting the full-year impact of the health segment. Acquisition expenses rose 43%, further pressuring margins, while dividends remained unchanged at PKR 15 per share.
What should investors expect going forward?
Investors should expect continued premium growth supported by new product launches across health, pension, and annuity segments. Expansion into VPS and corporate retirement solutions may diversify revenue streams. However, profitability may remain sensitive to investment income trends and claims growth, particularly from health insurance exposure. The investment portfolio remains positioned in short-term and floating-rate instruments with yields around 11–12% and duration under one year. Regulatory changes, including IFRS transition and higher capital requirements, will shape the operating environment. Industry risks such as taxation changes and inflationary pressures may influence future growth and margin stability.
📢 Announcement: We're on WhatsApp – Join Us There!
⚠️ This post reflects the author’s personal opinion and is for informational purposes only. It does not constitute financial advice. Investing involves risk and should be done independently. Read full disclaimer →
Comments (2)
Great insights from the EFUL briefing—its strong premium growth is certainly encouraging, but the pressure on earnings due to lower investment returns and rising claims does highlight some key challenges. It’s interesting to see how the company is navigating regulatory changes and portfolio positioning, especially with the shift toward more sustainable long-term growth. The forward outlook seems cautiously optimistic, which aligns with the broader industry trends we’re seeing.
EFUL’s top-line growth is impressive, but the earnings lag really highlights the challenges in managing claims and investment returns. It will be interesting to see if their planned product expansion can help improve profitability while navigating these pressures.